Immunophotonics, Inc. is grateful to NCI (the National Cancer Institute of NIH) and its SBIR Investor Initiatives Team for sponsoring Immunophotonics to present its technology and novel approach to cancer treatment at the BIO CEO & Investor Conference taking place February 6 – 9, 2023 at the New York Marriot Marquis in New York City. This is one of the largest biotech investor conferences focused on established and emerging biotech companies. As this event primarily features publicly traded biotech companies, Immunophotonics will be one of a select few privately held companies to present.
Lu Alleruzzo, CEO of Immunophotonics, will be giving his presentation on February 7th at 2:15 pm (EST). Please join us to see why our lead asset IP-001, a first-in-class molecule, is pioneering a new frontier in immuno-oncology.
